vimarsana.com

Page 542 - பல்கலைக்கழகம் ஆஃப் வடக்கு கரோலினா இல் தேவாலயம் மலை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Helping spread the WCU message for 30 years

Helping spread the WCU message for 30 years
themountaineer.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themountaineer.com Daily Mail and Mail on Sunday newspapers.

Latham & Watkins Adds Capital Markets Partner in New York

Latham & Watkins Adds Capital Markets Partner in New York Arrival of Alison Haggerty further enhances the firm s leading position in the technology and life sciences sectors. News provided by Share this article NEW YORK, Dec. 21, 2020 /PRNewswire/ Latham & Watkins LLP 1 is pleased to announce that Alison (Ali) Haggerty has joined the firm s New York office as a partner in the Capital Markets Practice within the Corporate Department. Haggerty advises issuers, predominantly in the technology and life sciences industries, and underwriters on capital markets transactions, with a particular emphasis on initial public offerings, follow-on equity offerings, and convertible debt offerings. She also regularly counsels publicly-traded companies on general corporate and securities law matters, including governance issues, reporting obligations, and stock exchange rules and requirements.

Full-Dose Clot Prophylaxis Halted for Severe COVID-19 in NHLBI Trial

Preemptive therapeutic-level heparin appeared futile and possibly unsafe for COVID-19 patients in three large-scale international trials. Interim analyses comparing that strategy against typical prophylactic dosing reached the prespecified threshold for futility among patients enrolled from the ICU in the National Heart, Lung, and Blood Institute (NHLBI)-sponsored trial, showing no reduction in the need for organ support. The data safety monitoring boards of the three adaptive platform trials the National Heart, Lung, and Blood Institute (NHLBI)-sponsored ACTIV-4 trial, REMAP-CAP, and ATTACC also indicated concerns regarding the overall safety of therapeutic anticoagulation in the severe illness at enrollment cohort, a letter to ACTIV-4 enrolling sites noted, so enrollment in that group is on pause.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.